Evaluation of the Efficacy and Safety of 102D-6 in the Treatment of Acute Uncomplicated Influenza
Key facts
- Who runs it
- Capital Medical University
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- Phase
- Phase 2/3
- People taking part
- 570 people, planned
- Started
- 21 Oct 2026
- Expected to end
- 30 Mar 2027
- Type of study
- Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- 20 mg 102D-6 dry suspension
- 40 mg 102D-6 dry suspension
- Placebo
- Record updated
- 26 October 2026
Who can take part
- Age
- 12 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Aged 18 to 65 years (including cut-off value), male or female
- Patients in the screening period met the following criteria:; Rapid influenza diagnostic test (RIDT) or polymerase chain reaction (PCR) test positive; Pyrexial (axillary temperature ≥ 37.3 °C). If antipyretic drugs (including Chinese patent medicines) are taken, the axillary temperature should be ≥ 37.3 °C after administration(more than 4 hours); At least one Influenza viral infections-related General symptoms (Headache, Pyrexial or chills, muscle or Soreness of joint, Lassitude) score ≥ 2 points; At least one Influenza viral infections-related respiratory symptom (Coughing, Pharyngalgia, Nasal obstruction) score ≥ 2 points
- The first occurrence of influenza symptoms ≤ 48 hours from the time of patient randomization
- Aged 12 to 65 years (including cut-off value), male or female
- Patients in the screening period met the following criteria:; Rapid influenza diagnostic test (RIDT) or polymerase chain reaction (PCR) test positive; Fever ≥ 37.3 °C(axillary temperature) at Screening. If antipyretic drugs (including Chinese patent medicines) are taken, the axillary temperature should be ≥ 37.3 °C after administration(more than 4 hours); At least one Influenza viral infections-related General symptoms (Headache, Pyrexial or chills, muscle or Soreness of joint, Lassitude) score ≥ 2 points; At least one Influenza viral infections-related respiratory symptom (Coughing, Pharyngalgia, Nasal obstruction) score ≥ 2 points
- The first occurrence of influenza symptoms ≤ 48 hours from the time of patient randomization
- Aged 18 to 65 years (including cut-off value), male or female
- Patients in the screening period met the following criteria:; Rapid influenza diagnostic test (RIDT) or polymerase chain reaction (PCR) test positive; Pyrexial (axillary temperature ≥ 37.3 °C). If antipyretic drugs (including Chinese patent medicines) are taken, the axillary temperature should be ≥ 37.3 °C after administration(more than 4 hours); At least one Influenza viral infections-related General symptoms (Headache, Pyrexial or chills, muscle or Soreness of joint, Lassitude) score ≥ 2 points; At least one Influenza viral infections-related respiratory symptom (Coughing, Pharyngalgia, Nasal obstruction) score ≥ 2 points
- The first occurrence of influenza symptoms ≤ 48 hours from the time of patient randomization
- Aged 12 to 65 years (including cut-off value), male or female; 2.Patients in the screening period met the following criteria:
- Rapid influenza diagnostic test (RIDT) or polymerase chain reaction (PCR) test positive
- Fever ≥ 37.3 °C(axillary temperature) at Screening. If antipyretic drugs (including Chinese patent medicines) are taken, the axillary temperature should be ≥ 37.3 °C after administration(more than 4 hours)
- At least one Influenza viral infections-related General symptoms (Headache, Pyrexial or chills, muscle or Soreness of joint, Lassitude) score ≥ 2 points
- At least one Influenza viral infections-related respiratory symptom (Coughing, Pharyngalgia, Nasal obstruction) score ≥ 2 points; 3.The first occurrence of influenza symptoms ≤ 48 hours from the time of patient randomization
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 12 and 65 years old?
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The goal of this Phase II/III study is to investigate the safty and efficacy of 102D-6 in adolescents and adults with influenza.
Read full original descriptionShow less
The main aim to answer:
1. Phase II study is to evaluate the efficacy of 102D-6 in the treatment of adult influenza subjects and determine the optimal therapeutic dose by analyzing the time of virus titer turning to negative. The results will be used to design the Phase III study. 2. Phase III study is to evaluate the efficacy of 102D-6 by analyzing the duration of remission of all influenza symptoms in adolescents and adults subjects with influenza.
Participants will be taken 102D-6/Placebo once, and be observed by 15 days.
The 3 groups in the trial
- 102D-6 low dose groupTreatment being tested
20 mg of 102D-6 dry suspension Once during the whole study. Based on the analysis of phase II, arms not selected will be discontinued
Treatment: 20 mg 102D-6 dry suspension
- 102D-6 high dose groupTreatment being tested
40 mg of 102D-6 dry suspension Once during the whole study. Based on the analysis of phase II, arms not selected will be discontinued
Treatment: 40 mg 102D-6 dry suspension
- Placebo controlPlacebo, for comparison
Analog dry suspension with no active ingredient.
Treatment: Placebo
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Randomized, Double-blind, Multicenter, Phase II/III Study to Evaluate the Efficacy and Safety of 102D-6 in the Treatment of Uncomplicated Influenza.
- Criteria questions
- Built from NCT07893847, who can take part
- Record updated
- 26 October 2026